Can-Fite BioPharma Secures FDA Approval for Namodenoson, Boosting Hope for Autoimmune and Cancer Treatments
Can-Fite BioPharma has secured FDA approval for the compassionate use of its asset Namodenoson, a potential breakthrough for patients with autoimmune-inflammatory diseases and cancer.
2 minutes to read